"After having "constructive conversations with stakeholders," Hims decided to stop offering the treatment, the company said in a post on X Saturday."
"Hims on Thursday announced plans to sell a cheaper version of Novo Nordisk A/S's new Wegovy weight-loss pill."
"The makers of blockbuster GLP-1 drugs, Novo and Eli Lilly & Co., have long complained the FDA hasn't done enough to stop the proliferation of cheap, compounded weight-loss drugs."
Hims & Hers launched a copycat version of Novo Nordisk's Wegovy weight-loss pill and stopped selling it two days later. The U.S. Food and Drug Administration announced a crackdown on copycat weight-loss treatments and the Department of Health and Human Services referred Hims to the Department of Justice for possible federal law violations. Novo Nordisk had called the Hims move illegal and threatened action. Makers of GLP-1 drugs have pressed the FDA over cheap compounded products. Telehealth companies began selling knock-off weight-loss drugs during an earlier supply shortage, and that practice has continued.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]